Basit öğe kaydını göster

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial

dc.contributor.authorIkeda, Hiroko
dc.contributor.authorPelov, Diana
dc.contributor.authorRidolfi, Antonia
dc.contributor.authorFan, Jenna
dc.contributor.authorDlugos, Dennis J.
dc.contributor.authorde Vries, Petrus J.
dc.contributor.authorNabbout, Rima
dc.contributor.authorCuratolo, Paolo
dc.contributor.authorFranz, David N.
dc.contributor.authorLawson, John A.
dc.contributor.authorPolster, Tilman
dc.contributor.authorYapici, Zuhal
dc.contributor.authorFrench, Jacqueline A.
dc.contributor.authorVoi, Maurizio
dc.date.accessioned2021-03-04T08:57:00Z
dc.date.available2021-03-04T08:57:00Z
dc.date.issued2018
dc.identifier.citationCuratolo P., Franz D. N. , Lawson J. A. , Yapici Z., Ikeda H., Polster T., Nabbout R., de Vries P. J. , Dlugos D. J. , Fan J., et al., "Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial", LANCET CHILD & ADOLESCENT HEALTH, cilt.2, sa.7, ss.495-504, 2018
dc.identifier.issn2352-4642
dc.identifier.othervv_1032021
dc.identifier.otherav_65ed2d75-a910-4861-8d98-b69962b6b53e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/70820
dc.identifier.urihttps://doi.org/10.1016/s2352-4642(18)30099-3
dc.description.abstractBackground Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.
dc.language.isoeng
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectPEDİATRİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.titleAdjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial
dc.typeMakale
dc.relation.journalLANCET CHILD & ADOLESCENT HEALTH
dc.contributor.departmentUniversity of Rome Tor Vergata , ,
dc.identifier.volume2
dc.identifier.issue7
dc.identifier.startpage495
dc.identifier.endpage504
dc.contributor.firstauthorID254706


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster